Elizabeth Dees, MD
Medical Oncology · Chapel Hill, NCNPI 1578631644
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,808 of the $13,820 with a category attached, or 99.9%. Sanofi-aventis U.S. LLC accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest.
Across 4 payments — averaging $3454.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$14K
- Gilead$12
Across 300 payments — averaging $10,351 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$968K
- Pfizer$851K
- Bayer$402K
- Boehringer Ingelheim$363K
- Merck$219K
- Puma Biotechnology, Inc.$64K
- plus $239K from 7 others
What the payments were for
- Consulting fees$13,808100%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 3 | $13,808 |
| Gilead | 1 | $12 |
How this compares
$13,820 in reported general payments places this provider in the 75th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 17 | $248,548 |
| VerzenioAbemaciclib | 14 | $213,847 |
| Exemestane | 78 | $10,847 |
| Toremifene Citrate | 12 | $8,889 |
| Letrozole | 324 | $6,618 |
| Tamoxifen Citrate | 49 | $1,359 |
| Anastrozole | 80 | $577 |
| Ibandronate Sodium | 16 | $201 |
| Gabapentin | 11 | $190 |
| Prochlorperazine Maleate | 13 | $140 |
| Clonazepam | 11 | $10 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Chapel Hill
- Thomas StinchcombeChapel Hill$281K
- Carey AndersChapel Hill$119K
- Natalie GroverChapel Hill$77K
- Shetal PatelChapel Hill$6K
- Joannie IvoryChapel Hill$5K
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.